Sanofi-Aventis and Bristol-Myers Squibb have cut a deal with a generic company that could keep a copycat version of their multibillion drug Plavix off the market until 2011. Sanofi-Aventis and Bristol ...

With our free press under threat and federal funding for public media gone, your support matters more than ever. Help keep the LAist newsroom strong, become a monthly member or increase your support ...

News of the expanded indication comes during a showdown between the marketer/manufacturer of the drug, Bristol-Myers Squibb (BMS)/Sanofi-Aventis, and Canadian drug company Apotex, which started ...

Patients who take a commonly prescribed drug have been warned of four potential side effects. According to the NHS, these ...

LONDON (Reuters) - Sanofi-Aventis and Bristol-Myers Squibb , which are just recovering from defeating generic competition to their top-selling Plavix drug in the United States, now face a similar ...

The Justice Department is investigating a deal between two large brand-name drug makers and a generic company. The deal allegedly was made to keep a cheaper, generic form of Plavix off the market for ...

Starting in October, drug companies will start rolling out generic versions of several widely used but expensive drugs. The top two sellers are the cholesterol drug Lipitor and the blood-thinner ...

The NHS states: "Like all medicines, clopidogrel can cause side effects, although not everyone gets them. These common side ...